PNEUMOCOCCAL IMMUNIZATION
Clinical trials for PNEUMOCOCCAL IMMUNIZATION explained in plain language.
Never miss a new study
Get alerted when new PNEUMOCOCCAL IMMUNIZATION trials appear
Sign up with your email to follow new studies for PNEUMOCOCCAL IMMUNIZATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New 21-Valent vaccine aims to shield infants from pneumococcal infections
⭐️ VACCINE ⭐️ OngoingThis study tests a new 21-valent pneumococcal vaccine (PCV21) in about 1,092 healthy infants and toddlers to see if it is safe and helps their bodies build defenses against pneumococcal bacteria. The vaccine is given alongside routine childhood shots at ages 2, 4, and 11-15 month…
Matched conditions: PNEUMOCOCCAL IMMUNIZATION
Phase: PHASE3 • Sponsor: Sanofi • Aim: ⭐️ VACCINE ⭐️
Last updated May 26, 2026 09:07 UTC
-
New 21-Valent vaccine aims to shield infants from pneumococcal infections
⭐️ VACCINE ⭐️ OngoingThis study tests a new vaccine (PCV21) that protects against 21 types of pneumococcal bacteria in healthy infants. About 2,360 babies will receive either the new vaccine or a current one at 2, 4, 6, and 12-15 months old. The main goal is to check for side effects and ensure the n…
Matched conditions: PNEUMOCOCCAL IMMUNIZATION
Phase: PHASE3 • Sponsor: Sanofi • Aim: ⭐️ VACCINE ⭐️
Last updated May 26, 2026 08:59 UTC
-
New vaccine combo could better shield babies from pneumococcal disease
⭐️ VACCINE ⭐️ OngoingThis study tests whether giving a new 21-valent pneumococcal vaccine after one, two, or three doses of a licensed 20-valent vaccine is safe and helps babies build strong immunity. About 580 healthy infants and toddlers will receive the vaccines at routine checkups. The goal is to…
Matched conditions: PNEUMOCOCCAL IMMUNIZATION
Phase: PHASE3 • Sponsor: Sanofi • Aim: ⭐️ VACCINE ⭐️
Last updated May 26, 2026 08:35 UTC
-
New 21-Valent vaccine aims to shield babies from pneumonia and meningitis
⭐️ VACCINE ⭐️ OngoingThis study tests a new vaccine (PCV21) in healthy infants to see if it safely helps their bodies build defenses against pneumococcal bacteria, which can cause serious illnesses like pneumonia and meningitis. About 1,700 babies will receive either the new vaccine or an existing on…
Matched conditions: PNEUMOCOCCAL IMMUNIZATION
Phase: PHASE3 • Sponsor: Sanofi Pasteur, a Sanofi Company • Aim: ⭐️ VACCINE ⭐️
Last updated May 26, 2026 08:34 UTC